Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Precision BioSciences, Inc.

Market Cap 160M 138M 127M 119M 224M 15.16B 227M 1.5B 584M 7.42B 601M 589M 25.7B P/E Ratio 2026 *
-2.27x
P/E Ratio 2027 * -2.44x
Enterprise Value 160M 138M 127M 119M 224M 15.16B 227M 1.5B 584M 7.42B 601M 589M 25.7B EV / Sales 2026 *
8.52x
EV / Sales 2027 * 12.8x
Free-Float
93.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day+1.61%
1 week-6.79%
Current month-9.47%
1 month-13.20%
3 months+11.29%
6 months+31.46%
Current year+51.68%
1 week 6.03
Extreme 6.03
7.17
1 month 6
Extreme 6
8.22
Current year 3.53
Extreme 3.53
8.59
1 year 3.53
Extreme 3.53
8.82
3 years 3.53
Extreme 3.53
21.9
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 2021-10-14
Chief Tech/Sci/R&D Officer 53 2006-01-25
Director of Finance/CFO 59 2020-12-31
Director TitleAgeSince
Chairman 68 2020-10-31
Director/Board Member 65 2020-03-09
Director/Board Member 67 2021-04-11
Date Insider Type Main position Quantity % Market Cap.
Jun. 02Free

Director

20,979 0.0872%
Jun. 02Free

Director

20,979 0.0872%
Jun. 02Free

Director

20,979 0.0872%
Change 5-day change 1-year change 3-year change Capi.($)
+1.61%-6.79%+28.78%-69.03% 160M
-0.12%+1.04%-13.08%-12.43% 43.58B
-2.17%+5.45%+285.76%+522.83% 34.03B
+0.44%-2.46%+14.20%-17.35% 29.77B
-1.60%-2.54%-2.12%+31.28% 29.82B
-0.29%+9.47%+13.95%+21.93% 25.42B
+3.54%+12.34% - - 13.87B
-1.26%+0.81%+54.77%+109.24% 13.35B
-1.04%-3.33%+3.98%+3.91% 12.85B
-1.18%-0.61%+105.37%+75.32% 12.22B
Average -0.21%+1.00%+54.62%+73.97% 21.51B
Weighted average by Cap. -0.54%+2.01%+59.36%+102.58%

Financials

2026 *2027 *
Net sales 18.81M 16.2M 14.91M 14.01M 26.31M 1.78B 26.62M 176M 68.61M 871M 70.58M 69.09M 3.02B 12.52M 10.79M 9.93M 9.32M 17.52M 1.18B 17.72M 117M 45.67M 580M 46.98M 45.98M 2.01B
Net income -77.69M -66.93M -61.6M -57.86M -109M -7.35B -110M -726M -283M -3.6B -292M -285M -12.46B -86.26M -74.31M -68.39M -64.24M -121M -8.16B -122M -807M -315M -3.99B -324M -317M -13.83B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
66
Date Price Change Volume
26-06-16 6.290 $ +1.29% 209,187
26-06-15 6.210 $ +1.80% 144,271
26-06-12 6.100 $ -1.13% 236,183
26-06-11 6.170 $ -4.34% 432,210
26-06-10 6.450 $ -5.98% 319,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.210USD
Average target price
29.60USD
Spread / Average Target
+376.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!